Karyopharm Therapeutics Inc. (KPTI)
| Market Cap | 11.74M -77.9% |
| Revenue (ttm) | 146.62M +6.8% |
| Net Income | -224.74M |
| EPS | -11.58 |
| Shares Out | 22.68M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,963,966 |
| Open | 0.5366 |
| Previous Close | 0.5461 |
| Day's Range | 0.4400 - 0.5550 |
| 52-Week Range | 0.3100 - 10.9900 |
| Beta | 1.04 |
| Analysts | Buy |
| Price Target | 7.25 (+1,300.97%) |
| Est. Earnings | Nov 6, 2026 |
About KPTI
Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compounds include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myelom... [Read more]
Financial Performance
In 2025, Karyopharm Therapeutics's revenue was $146.07 million, an increase of 0.57% compared to the previous year's $145.24 million. Losses were -$196.04 million, 156.5% more than in 2024.
Financial StatementsAnalyst Summary
According to 5 analysts, the average rating for KPTI stock is "Buy." The 12-month stock price target is $7.25, which is an increase of 1,300.97% from the latest price.
News
Karyopharm Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
NEWTON, Mass., Oct. 1, 2026 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company g...
Karyopharm, guarantors enter into forbearance agreement
In a regulatory filing, Karyopharm (KPTI) announced that the company and its subsidiary guarantors entered into a Forbearance Agreement and Limited Waiver to Indentures to provide the company with add...
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEWTON, Mass., Sept. 1, 2026 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company ...
Karyopharm submits sNDA to FDA for XPOVIO
Karyopharm (KPTI) Therapeutics announced that it has submitted a supplemental New Drug Application, sNDA, to the U.S. Food and Drug Administration, FDA, seeking Accelerated Approval for XPOVIO in comb...
Karyopharm Submits Supplemental New Drug Application to the FDA for XPOVIO® (selinexor) Plus Ruxolitinib for Patients with Myelofibrosis
– sNDA Submitted under the Accelerated Approval Pathway; Priority Review Requested – NEWTON, Mass., Aug. 31, 2026 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharma...
Karyopharm reports Q2 EPS ($2.32) vs. ($4.32) last year
Reports Q2 revenue $33.4M, consensus $32.19M. “Our planned submission under the Accelerated Approval pathway represents the beginning of an important new chapter for Karyopharm (KPTI) and an important...
Karyopharm Therapeutics Earnings Call Transcript: Q2 2026
Selinexor advanced toward sNDA submission for myelofibrosis, supported by strong phase III data and constructive FDA engagement. Q2 revenue was $33.4M, with stable XPOVIO sales and disciplined expense management. Liquidity risks remain, but financing options are being pursued.
Karyopharm Therapeutics Earnings release: Q2 2026
Karyopharm Therapeutics released its Q2 2026 earnings on August 13, 2026, summarizing the period's financial results.
Karyopharm Therapeutics Quarterly report: Q2 2026
Karyopharm Therapeutics has published its Q2 2026 quarterly earnings report on August 13, 2026.
Karyopharm Therapeutics Slides: Q2 2026
Karyopharm Therapeutics has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 13, 2026.
Karyopharm Reports Second Quarter 2026 Financial Results and Highlights Continued Progress Toward Myelofibrosis sNDA Submission
– Planned August sNDA Submission for Selinexor in Combination with Ruxolitinib in Myelofibrosis under the Accelerated Approval Pathway Remains on Track – – Planned sNDA for Selinexor plus Ruxolitinib ...
Karyopharm to Report Second Quarter 2026 Financial Results on August 13, 2026
-- Conference Call Scheduled for Thursday, August 13, 2026, at 8:00 a.m. ET -- NEWTON, Mass.
Karyopharm price target lowered to $11 from $14 at Jefferies
Jefferies lowered the firm’s price target on Karyopharm (KPTI) to $11 from $14 and keeps a Buy rating on the shares. The company’s latest update is “mixed to slightly negative”…
Karyopharm price target lowered to $7 from $16 at Piper Sandler
Piper Sandler analyst Edward Tenthoff lowered the firm’s price target on Karyopharm (KPTI) to $7 from $16 and keeps an Overweight rating on the shares. The Phase III XPORT-EC-042 trial…
Karyopharm downgraded to Neutral from Buy at H.C. Wainwright
H.C. Wainwright analyst Robert Burns downgraded Karyopharm (KPTI) to Neutral from Buy with a price target of $3, down from $13. The XPORT-EC-042 primary endpoint miss weighs on Karyopharm’s investment...
Karyopharm downgraded to Neutral from Outperform at Baird
Baird downgraded Karyopharm (KPTI) to Neutral from Outperform with a price target of $3, down from $15. The company’s data from the Phase 3 XPORT-EC-042 study evaluating selinexor as a…
Karyopharm down 69% after XPORT-EC-042 trial did not meet primary endpoint
18:19 EDT Karyopharm (KPTI) down 69% after XPORT-EC-042 trial did not meet primary endpoint
Karyopharm to submit sNDA for selinexor plus ruxolitinib
Karyopharm (KPTI) Therapeutics announced that it plans to submit a supplemental New Drug Application to the U.S. FDA in August 2026 seeking accelerated approval of selinexor in combination with ruxoli...
Karyopharm’s endometrial cancer candidate did not meet Phase 3 primary endpoint
Karyopharm (KPTI) announced topline results from its Phase 3 XPORT-EC-042 trial evaluating selinexor as a maintenance-only therapy compared to placebo in adult patients with TP53 wild-type advanced or...
Karyopharm trading halted, news pending
16:01 EDT Karyopharm (KPTI) trading halted, news pending
Karyopharm Plans to Submit sNDA for Selinexor Plus Ruxolitinib in Myelofibrosis Under Accelerated Approval Pathway
– Company Plans to Submit sNDA in August 2026 and Will Request Priority Review – – Following FDA Engagements, Company Plans to Submit sNDA under Accelerated Approval Based Upon Compelling SVR35 Data a...
Karyopharm Announces Topline Results from Phase 3 XPORT-EC-042 Trial in Endometrial Cancer
– The Trial Did Not Meet the Primary Endpoint of Progression-Free Survival (PFS) – – A Trend Favoring the Selinexor Arm was Observed with a 5.3 Month Improvement in Median PFS Relative to the Placebo ...
Karyopharm sinks after revealing executive cash retention program
Shares of Karyopharm (KPTI) are trading lower after the company on Friday night disclosed that its board implemented a retention program for certain employees. “The purpose of the 2026 Leadership…
RBC says Karyopharm weakness after compensation plan a buying opportunity
RBC Capital notes Karyopharm (KPTI) shares are down 28% today after the company updated their incentive compensation plan on Friday after the close, adding that the firm has received a…